Your latest specialty news including hair transplant tragedy and BDD research

This week’s Aesthetics newsletter highlights a PubMed review of 3,433 peer-reviewed articles, identifying botulinum toxin as the number one performed non-surgical aesthetic treatment globally. It can be argued that?the aesthetic use of botulinum toxin in this way gave birth to medical aesthetics, with the product being extensively researched over the years.

This week’s newsletter also delves into concerns surrounding a recent hair transplant-related death in Turkey and provide insights from Teoxane UK Limited 's educational XPAND conference.

Become an Elite member of Aesthetics today to find out more and earn 1 CPD point by exploring this month's article focusing on the pharmacodynamics of botulinum toxin.

More from the aesthetics news this week...

• Dibi Milano UK and APD Tech host congress in Italy
• Sisneo Bioscience releases new Mesolux treatment devices
• New research uncovers links between BDD and shame
• Hydrafacial launches new Hydralock HA booster

And so much more...

CPD: Optimising Facial Botulinum Toxin Results

The use of botulinum toxin in aesthetics began in the 1980s when Dr. Jean and Dr. Alastair Carruthers discovered its effect on reducing glabellar lines while treating blepharospasm. Their groundbreaking 1992 study on onabotulinumtoxinA (Botox) transformed the field of aesthetics. In the latest Aesthetics Journal CPD article, Dr. Nestor Demosthenous explores the pharmacodynamics of botulinum toxin and compares different available formulations.

Get 1 CPD point by becoming an Elite member of Aesthetics.

Have you secured your place at ACE 2025?

Have you registered for ACE 2025? Join us on March 14-15 at London’s Business Design Centre for a premier educational experience. Dive into the science of aesthetics, learn from experts, and explore the latest innovations.

Register FREE today!